Stephen L. Chan - Concepedia

Author

Stephen L. Chan

Also Known As

-L Chan, Andrea Casadei-Gardini, Chan, S.L., Chan, Stephen, Chan, Stephen L, Chan, Stephen L., I.B. Tan, L Chan, L. Chan, Lam Chan

730

Publications

36.3K

Citations

H-Index

196

Concepts

All Affiliations

Chinese University of Hong Kong Prince of Wales Hospital Asan Medical Center University of Ulsan National Taiwan University Hospital

About

Stephen L. Chan is an author at Chinese University of Hong Kong specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	22	32	4.8K
2	Management	3	3	193
3	Business	2	2	133
4	Engineering	2	2	87
5	Education	1	1	111

Stephen L. Chan

210

Publications

30.3K

Citations

H-Index

Page 1

	Year	Citations
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade Philip J. Johnson, Sarah Berhane, Chiaki Kagebayashi, Journal of Clinical Oncology	2014	2.6K
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, New England Journal of Medicine	2018	2.3K
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Journal of Clinical Oncology	2019	1.8K
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, NEJM Evidence	2022	1.3K
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments Kun Sun, Peiyong Jiang, K.C. Allen Chan, Proceedings of the National Academy of Sciences	2015	794
Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer K.C. Allen Chan, John K. S. Woo, Ann D. King, New England Journal of Medicine	2017	757
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients Peiyong Jiang, Carol W. M. Chan, K.C. Allen Chan, Proceedings of the National Academy of Sciences	2015	739
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Shukui Qin, Stephen L. Chan, Shanzhi Gu, The Lancet First-line TherapyHepatologyInternational Phase 3MedicinePathology	2023	590

Page 1